2B or Not 2B? That Was the Question for Aspartame
In March 2015, the World Health Organization's International Agency for Research on Cancer (IARC) designated glyphosate, the active ingredient in Roundup, as "probably ...
Content from Adam Grossman
Adam Grossman, Ph.D., is Praedicat’s Senior Scientist and Vice President of Modeling.
D&O Underwriters May Be Worried About the Wrong Greenhouse Gas
Greenwashing lawsuits, while still relatively uncommon, have seen an uptick in recent years, with some alleging harm to consumers and others alleging harm to ...
Endocrine Disruption Litigation Has Arrived
How long does it take for science to identify a new type of harm from commercial activity before litigation tries to hold the businesses accountable?
3M Belgian Settlement Signals Increased Risk of ‘Toxic Torts’ in Europe
"Toxic torts," which are lawsuits alleging damage to human health or the environment caused by specific substances, are increasingly common in the United States. They can cost defendants hundreds of ...
Pesticides: The New Pharma?
Fen-phen, Baycol, Rezulin, Vioxx… The 1990s and 2000s saw a tidal wave of pharmaceutical-related litigation that dominated the agenda of the plaintiffs' bar. Mass torts over the negative health ...
The Next Wave of Climate Change Litigation: Industrial Meat
Many insurers think they have climate casualty risk managed by virtue of avoiding writing the oil and gas industry or with limitations on their policies. Climate casualty risk is broader than this ...
What Do You Do With Emerging Interest Risks?
Every emerging risk strategy must begin with a horizon scan. At Praedicat, our strategy is to scan the scientific literature for indications that scientists are investigating a new hypothesis that ...
PFAS Litigation Levels Already at Epic Proportions
Mass litigation is every casualty insurer's worst nightmare, conjuring up memories of the unending flow of asbestos litigation and the devastating effect it had on the industry. Today, though, we're ...
Opioids Are the Next Tobacco. Are Antibiotics the Next Opioids?
The fact pattern is familiar. Drug companies market a legal and regulated drug, resulting in significant overprescription of that drug. Over time, a public health crisis emerges and annual deaths ...
Pandemic Risk: Finding the Opportunity in Liability
Liability insurers frequently use exclusions to help address emerging risks that are viewed as unpredictable, intractable and potentially very large. It comes as no surprise, then, that the emergence ...